Laddar populära aktier...
Media keeps delivering like clockwork, 18% organic growth in Q2 We remove Platform and Sportsbook fr...
Limited estimate revisions after solid Q2 with several promising signs Base machine is working, scal...
Även om Cell impacts utveckling går långsammare än vi tidigare prognosticerat bedömer vi att Cell Im...
Loihde’s Q2 was better than estimated, profitability in particular, with adj.
Embark Group AB (”Embark” eller ”Bolaget”) fortsatte under det andra kvartalet att kapitalisera på t...
Nettoomsättningen i det andra kvartalet uppgick till 202,7 MSEK (203,9), en minskning med cirka 0,6 ...
First Venture Sweden (”First Venture” eller ”Bolaget”) är ett investmentbolag med fokus på snabbväxa...
Q2: 21% ARR growth in line, FCF of DKK -4m vs. ABGSCe DKK -6m Reiterates FY'24 guidance, as expected...
Redeye’s initial take on Xbrane’s Q2 report is that end-customer sales and profit split were higher ...
Redeye updates its view on Lifecare following the Q2 report and recent company developments, includi...
Redeye makes mixed estimate revisions on the back of Nekkar’s H1’24 report that beat our EPS forecas...
Weak Q2 margin of 5.0% (7.3%), but book-to-bill improved to 0.
Prostatype Genomics har nyligen lanserat sitt test Prostatype® på den viktiga amerikanska marknaden ...
Market headwinds continued in Q2 We lower 2025e EBIT on slower recovery in activity Easy comps in '2...
Redeye leaves a comment relating to the announcement of Werfen and its new POC system GEM Premier 70...